Emodin, a natural product, selectively inhibits 11β-hydroxysteroid dehydrogenase type 1 and ameliorates metabolic disorder in diet-induced obese mice

British Journal of Pharmacology

Volumn 161, Issue 1, 2010, Pages 113-126

  Feng, Ying ^a   Huang, Su Ling ^a   Dou, Wei ^a   Zhang, Song ^a   Chen, Jun Hua ^a   Shen, Yu ^a   Shen, Jian Hua ^a   Leng, Ying ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

11 hydroxysteroid dehydrogenase type 1; diet induced obese mice; emodin; insulin resistance; metabolic syndrome; type 2 diabetes

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; 3 METHYLCHRYSAZIN; ALOE EMODIN; ANTHRAQUINONE DERIVATIVE; DEXAMETHASONE; EMODIN; GLUCOSE; GLUCOSE 6 PHOSPHATASE; MESSENGER RNA; NATURAL PRODUCT; PHYSCION; PREDNISONE; RHEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C57BL 6 MOUSE; COMPETITIVE INHIBITION; CONTROLLED STUDY; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; IC 50; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; LIVER; MALE; METABOLIC DISORDER; METABOLIC SYNDROME X; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; SCINTILLATION; THERAPY EFFECT;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; ADRENAL CORTEX HORMONES; ANIMALS; CELL LINE; DEXAMETHASONE; DIET; DOSE-RESPONSE RELATIONSHIP, DRUG; EMODIN; HUMANS; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; MICE; MICE, INBRED C57BL; MODELS, MOLECULAR; OBESITY; PREDNISONE; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN KINASE INHIBITORS;

EID: 77955828684     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.00826.x     Document Type: Article

References (51)

1. Abdallah BM, Beck-Nielsen H, Gaster M (2005). Increased expression of 11beta-hydroxysteroid dehydrogenase type 1 in type 2 diabetic myotubes. Eur J Clin Invest 35 : 627 634.
2. Alberts P, Nilsson C, Selen G, Engblom LO, Edling NH, Norling S et al. (2003). Selective inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains. Endocrinology 144 : 4755 4762.
3. Andrews RC, Rooyackers O, Walker BR (2003). Effects of the 11 beta-hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes. J Clin Endocrinol Metab 88 : 285 291.
4. Beauregard C, Dickstein G, Lacroix A (2002). Classic and recent etiologies of Cushing's syndrome: diagnosis and therapy. Treat Endocrinol 1 : 79 94.
5. Cavagnini F, Croci M, Putignano P, Petroni ML, Invitti C (2000). Glucocorticoids and neuroendocrine function. Int J Obes Relat Metab Disord 24 : S77 S79.
6. Chang CH, Lin CC, Yang JJ, Namba T, Hattori M (1996). Anti-inflammatory effects of emodin from ventilago leiocarpa. Am J Chin Med 24 : 139 142. (Pubitemid 126765683)
7. Cole TJ, Blendy JA, Monaghan AP, Krieglstein K, Schmid W, Aguzzi A et al. (1995). Targeted disruption of the glucocorticoid receptor gene blocks adrenergic chromaffin cell development and severely retards lung maturation. Genes Dev 9 : 1608 1621.
8. DeFronzo RA, Ferrannnini E (1991). Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14 : 173 194.
9. Draper N, Stewart PM (2005). 11β-Hydroxysteroid dehydrogenase and the pre-receptor regulation of corticosteroid hormone action. J Endocrinol 86 : 251 271.
10. Engeli S, Böhnke J, Feldpausch M, Gorzelniak K, Heintze U, Janke J et al. (2004). Regulation of 11beta-HSD genes in human adipose tissue: influence of central obesity and weight loss. Obes Res 12 : 9 17.
11. Ewing T, Kuntz ID (1997). Critical evaluation of search algorithms for automated molecular docking and database screening. J Comput Chem 18 : 1175 1189.
12. Gasteiger J, Marsili M (1980). Iterative partial equalization of orbital electronegativity. Tetrahedron 36 : 3219 3228.
13. Gounarides JS, Korach-André M, Killary K, Argentieri G, Turner O, Laurent D (2008). Effect of dexamethasome on glucose tolerance and fat metabolism in a diet-induced obesity mouse model. Endocrinology 149 : 758 766.
14. Heo SK, Yun HJ, Park WH, Park SD (2008). Emodin inhibits TNF-alpha-induced human aortic smooth muscle cell proliferation via caspase and mitochondrial-dependent apoptosis. J Cell Biochem 105 : 70 80.
15. Hermanowski-Vosatka A, Balkovec JM, Cheng K, Chen HY, Hernandez M, Koo GC et al. (2005). 11Beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. J Exp Med 202 : 517 527.
16. Hu X, Feng Y, Liu X, Zhao XF, Yu JH, Yang YS et al. (2007). Effect of a novel non-thiazolidinedione peroxisome proliferators-activated receptor α/γ agonist on glucose uptake. Diabetologia 50 : 1048 1057.
17. Huang HC, Chang JH, Tung SF, Wu RT, Foegh ML, Chu SH (1992). Immunosuppressive effect of emodin, a free radical generator. Eur J Pharmacol 211 : 359 364.
18. Huang Q, Lu G, Shen HM, Chung MC, Ong CN (2007). Anti-cancer properties of anthraquinones from rhubarb. Med Res Rev 27 : 609 630.
19. Imai E, Stromstedt PE, Quinn PG, Carlstedt-Duke J, Gustafsson JA, Granner DK (1990). Characterization of a complex glucocorticoid response unit in the phosphoenolpyruvate carboxykinase gene. Mol Cell Biol 10 : 4712 4719.
20. Kotelevtsev Y, Holmes MC, Burchell A, Houston PM, Schmoll D, Jamieson P et al. (1997). 11beta-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc Natl Acad Sci 94 : 14924 14929.
21. Kuntz ID (1992). Structure-based strategies for drug design and discovery. Science 257 : 1078 1082.
22. Lambillotte C, Gilon P, Henquin JC (1997). Direct glucocorticoid inhibition of insulin secretion. An in vitro study of dexamethasone effects in mouse islets. J Clin Invest 99 : 414 423.
23. Lange AJ, Argaud D, el-Maghrabi MR, Pan W, Maitra SR, Pilkis SJ (1994). Isolation of a cDNA for the catalytic subunit of rat liver glucose-6- phosphatase: regulation of gene expression in FAO hepatoma cells by insulin, dexamethasone and cAMP. Biochem Biophys Res Commun 201 : 302 309.
24. Li Y, Duan J, Guo T, Xie W, Yan S, Li B et al. (2009). In vivo pharmacokinetics comparisons of icariin, emodin and psoralen from Gan-kang granules and extracts of Herba epimedii, Nepal dock root, Ficus hirta yahl. J Ethnopharmacol 124 : 522 529.
25. Lindsay RS, Wake DJ, Nair S, Bunt J, Livingstone DE, Permana PA et al. (2003). Subcutaneous adipose 11 beta-hydroxysteroid dehydrogenase type 1 activity and messenger ribonucleic acid levels are associated with adiposity and insulinemia in Pima Indians and Caucasians. J Clin Endocrinol Metab 88 : 2738 2744.
26. Livingstone DE, Jones GC, Smith K, Jamieson PM, Andrew R, Kenyon CJ et al. (2000). Understanding the role of glucocorticoids in obesity: tissue-specific alternations of corticosterone metabolism in obese Zucker rats. Endocrinology 141 : 560 563.
27. Lundgren M, Buren J, Ruge T, Myrnas T, Eriksson JW (2004). Glucocorticoids down-regulate glucose uptake capacity and insulin-signaling proteins in omental but not subcutaneous human adipocytes. J Clin Endocrinol Metab 89 : 2989 2997.
28. Marin P, Drain N, Amemiya T, Andersson B, Jern S, Bjorntorp P (1992). Cortisol secretion in relation to body fat distribution in obese premenopausal women. Metabolism 41 : 882 886.
29. Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR et al. (2001). A transgenic model of visceral obesity and the metabolic syndrome. Science 294 : 2166 2170.
30. Morton NM (2010). Obesity and corticosteroids: 11β-hydroxysteriod type 1 as a cause and therapeutic target in metabolic disease. Mol Cellular Endocrinol 316 : 154 164.
31. Morton NM, Holmes MC, Fiévet C, Staels B, Tailleux A, Mullins JJ et al. (2001). Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11beta-hydroxysteroid dehydrogenase type 1 null mice. J Biol Chem 276 : 41293 41300.
32. Morton NM, Paterson JM, Masuzaki H, Holmes MC, Staels B, Fievet C et al. (2004). Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11β-hydroxysteroid dehydrogenase type 1-deficient mice. Diabetes 53 : 931 938.
33. Mundt S, Solly K, Thieringer R, Hermanowski-Vosatka A (2005). Development and application of a scintillation proximity assay (SPA) for identification of selective inhibitors of 11β-hydroxysteroid dehydrogenase type 1. Assay Drug Dev Technol 3 : 367 375.
34. Nuotio-Antar AM, Hachey DL, Hasty AH (2007). Carbenoxolone treatment attenuates symptoms of metabolic syndrome and atherogenesis in obese, hyperlipidemic mice. Am J Physiol Endocrinol Metab 293 : E1517 E1528.
35. Pagano G, Cavallo-Perin P, Cassader M, Bruno A, Ozzello A, Masciola P et al. (1983). An in vivo and in vitro study of the mechanism of prednisone-induced insulin resistance in healthy subjects. J Clin Invest 72 : 1814 1820.
36. Patel JR, Shuai Q, Dinges J, Winn M, Pliushchev M, Fung S et al. (2007). Discovery of adamantane ethers as inhibitors of 11β-HSD-1: synthesis and biological evaluation. Bioorg Med Chem Lett 17 : 50 755.
37. Pilkis SJ, Granner DK (1992). Molecular physiology of the regulation of hepatic gluconeogenesis and glycolysis. Annu Rev Physiol 54 : 885 909.
38. Sandeep TC, Andrew R, Homer NZ, Andrews RC, Smith K, Walker BR (2005). Increased in vivo regeneration of cortisol in adipose tissue in human obesity and effects of the 11beta-hydroxysteroid dehydrogenase type 1 inhibitor carbenoxolone. Diabetes 54 : 872 879.
39. Seckl JR, Walker BR (2001). Minireview: 11beta-hydroxysteroid dehydrogenase type 1 - a tissue-specific amplifier of glucocorticoid action. Endocrinology 142 : 1371 1376.
40. Slavin BG, Ong JM, Kern PA (1994). Hormonal regulation of hormone-sensitive lipase activity and mRNA levels in isolated rat adipocytes. J Lipid Res 35 : 1535 1541.
41. Surwit RS, Kuhn CM, Cochrane C, McCubbin JA, Feinglos MN (1988). Diet-induced type II diabetes in C57BL/6J mice. Diabetes 37 : 1163 1167.
42. Taylor A, Irwin N, McKillop AM, Flatt PR, Gault VA (2008). Sub-chronic administration of 11β-HSD1 inhibitor, carbenoxolone, improves glucose tolerance and insulin sensitivity in mice with diet-induced obesity. Biol Chem 389 : 441 445.
43. Tomlinson JW, Sherlock M, Hughes B, Hughes SV, Kilvington F, Bartlett W et al. (2007). Inhibition of 11β-hydroxysteroid dehydrogenase type 1 activity in vivo limits glucocorticoid exposure to human adipose tissue and decreases lipolysis. J Clin Endocrinol Metab 92 : 857 864.
44. Valsamakis G, Anwar A, Tomlinson JW, Shackleton CH, McTernan PG, Chetty R et al. (2004). 11Beta-hydroxysteroid dehydrogenase type 1 activity in lean and obese males with type 2 diabetes mellitus. J Clin Endocrinol Metab 89 : 4755 4761.
45. Vegiopoulos A, Herzig S (2007). Glucocorticoids, metabolism and metabolic diseases. Mol Cell Endocrinol 275 : 43 61.
46. Walker BR, Connacher AA, Lindsay RM, Webb DJ, Edwards CR (1995). Carbenoxolone increases hepatic insulin sensitivity in man: a novel role for 11-oxosteroid reductase in enhancing glucocorticoid receptor activation. J Clin Endocrinol Metab 80 : 3155 3159.
47. Wang HH, Chung JG (1997). Emodin-induced inhibition of growth and DNA damage in the Helicobacter pylori. Curr Microbiol 35 : 262 266.
48. Wang SJ, Birtles S, de Schoolmeester J, Swales J, Moody G, Hislop D et al. (2006). Inhibition of 11β-hydroxysteroid dehydrogenase type 1 reduces food intake and weight gain but maintains energy expenditure in diet-induced obese mice. Diabetologia 49 : 1333 1337.
49. Weiner SJ, Kollman PA, Nguyen DT, Case DA (1986). An allatom force field for simulations of proteins and nucleic acids. J Comput Chem 7 : 230 252.
50. Woo SW, Nan JX, Lee SH, Park EJ, Zhao YZ, Sohn DH (2002). Aloe emodin suppresses myofibroblastic differentiation of rat hepatic stellate cells in primary culture. Pharmacol Toxicol 90 : 193 198.
51. Zhao XY, Qiao GF, Li BX, Chai LM, Li Z, Lu YJ et al. (2008). Hypoglycaemic and hypolipidaemic effects of emodin and its effect on L-type calcium channels in dyslipidaemic-diabetic rats. Clin Exp Pharmacol Physiol 36 : 29 34.